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Abstract
Background: Recurrent outbreaks of highly pathogenic H5N1 avian influenza virus pose a threat of eventually causing a
pandemic. Early vaccination of the population would be the single most effective measure for the control of an emerging
influenza pandemic.
Methodology/Principal Findings: Influenza virus-like particles (VLPs) produced in insect cell-culture substrates do not
depend on the availability of fertile eggs for vaccine manufacturing. We produced VLPs containing influenza A/Viet
Nam1203/04 (H5N1) hemagglutinin, neuraminidase, and matrix proteins, and investigated their preclinical immunogenicity
and protective efficacy. Mice immunized intranasally with H5N1 VLPs developed high levels of H5N1 specific antibodies and
were 100% protected against a high dose of homologous H5N1 virus infection at 30 weeks after immunization. Protection is
likely to be correlated with humoral and cellular immunologic memory at systemic and mucosal sites as evidenced by rapid
anamnestic responses to re-stimulation with viral antigen in vivo and in vitro.
Conclusions/Significance: These results provide support for clinical evaluation of H5N1 VLP vaccination as a public health
intervention to mitigate a possible pandemic of H5N1 influenza.
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Introduction
Influenza A is one of the major threats to human and animal
health due to its high transmissibility, and the potentially severe
morbidity and mortality among susceptible hosts. Early vaccina-
tion is one of the most effective means to mitigate a future
influenza pandemic [1]. Licensed influenza vaccines are chemi-
cally inactivated detergent-solubilized virions composed of hem-
agglutinin (HA) and lesser amounts of other virion proteins (i.e.
neuraminidase (NA)). Another vaccine licensed only for seasonal
influenza is a live, attenuated influenza virus vaccine (FluMistH)
intended for intranasal administration [2,3]. Both types of licensed
influenza vaccines rely on fertilized chicken eggs as substrates for
production [4]. Licensed seasonal influenza vaccines provide
incomplete protection [5], probably due in part to the limited
mucosal immunity and cytotoxic T cell immunity. Furthermore,
the protective immunity elicited by inactivated vaccines is of short
duration [4,6].
Wild birds are a source for 16 influenza A HA subtypes,
representing a large reservoir for novel glycoproteins to which the
human immune system is naı ¨ve [7–9]. In 1997, human infections
with avian influenza A H5N1 viruses resulted in 6 fatal deaths out
of 18 confirmed cases [10,11]. Since 2003, there have been 243
deaths out of 385 human cases of avian influenza A H5N1 virus, a
case fatality ratio higher than that of many viral hemorrhagic
fevers [12]. Outbreaks of highly pathogenic avian influenza viruses
in poultry and confirmed human cases are occurring at
unprecedented rates, and increase the risk of pandemic emergence
if the H5N1 virus acquires the capability to spread from person to
person [13,14]. Therefore, an effective vaccine against H5N1
influenza viruses would meet an important public health need.
Development and manufacturing of effective H5N1 vaccines
pose significant practical challenges. Handling of highly patho-
genic H5N1 influenza viruses requires biosafety level 3 laboratory
facilities. Manufacturing capacity is likely to be limited by
insufficient availability of fertile eggs to meet the surge in vaccine
demand during a pandemic. Unadjuvanted inactivated H5N1
vaccines require six times higher antigen doses than conventional
seasonal vaccines to elicit a comparable immune response; the use
of proprietary adjuvants may reverse this situation if they are
approved by regulatory authorities [15–21]. In attempts to
overcome these obstacles, several strategies have been explored
including the use of a low pathogenic avian influenza virus [22],
baculovirus- expressed H5 HA [23], recombinant adenoviruses
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4667[24,25] and the production of attenuated live seed virus with
modified H5 HA [17,26,27].
As an alternative to conventional egg-based influenza vaccine
manufacturing, our laboratory and others have developed non-
replicating virus-like particles (VLPs). VLPs are safer than virion-
derived vaccines by virtue of lacking a viral genome and retain high
immunogenicity because the HA antigen is presented to the host in
a native particulate form without chemical inactivation. The
expression of influenza proteins in a recombinant baculovirus
system yields VLPs which present conformational epitopes of
surface proteins to the immune system comparable to those of live
virions. Recent studies demonstrated that VLPs containing
influenza glycoproteins (HA or both HA and NA) and the influenza
matrix protein M1 induced high titers of virus-specific antibodies in
vaccinated mice or ferrets and provided immunized animals with
protection against otherwise lethal experimental infections [28–32].
To examine the feasibility of a VLP vaccine against a potentially
pandemic influenza virus, we generated influenza VLPs containing
A/Viet Nam/1203/04 hemagglutinin (HA) and neuraminidase
(NA) as well as M1, and investigated their immunogenicity, long-
term protective immunity, and immunologic memory responses.
Intranasal delivery of two doses of H5N1 VLPs to mice induced
long-lived antibody responsesand providedprotectionagainst lethal
challenge infections with wild type influenza H5N1 virus in dose-
range experiments. The H5N1 VLPs were observed to induce
humoral and cellular memory responses, which were rapidly
recalled upon re-exposure to viral antigen in vivo.
Results
Production of H5N1 VLPs
Influenza H5N1 VLPs were produced in insect cells co-infected
with three rBVs, each expressing A/Viet Nam/1203/2004, subtype
H5N1 (VN/04) virus HA, NA, or M1. Purified H5N1 VLPs were
found to contain HA (Fig. 1B) and NA (data not shown) proteins as
well as M1, as indicated by the SDS-PAGE and western blot analysis.
The H5 HA lacking a polybasic cleavage site in VLPs was expressed
as a single polypeptide (HA0) that was readily cleaved into HA
subunits upon trypsin treatment (Fig. 1C). H5N1 VLP preparations
hemagglutinated chicken erythrocytes with titers ,128 to 256 in
samples containing 1 mg of VLPs. In addition, negatively stained
preparations of H5N1 VLPs examined by transmission electron
microscopy revealed particles of 80–120 nm in diameter with spikes
on the surface resembling influenza virions (Fig. 1D). Therefore,
influenza H5N1 VLPs produced by cells infected with rBVs were
similar to influenza virions in structure, size, and morphology despite
lacking the viral ribonucleoprotein components.
Antibody responses to influenza H5N1 VLPs
Mice were immunized intranasally with H5N1 VLPs containing
0.1 mg or 0.3 mg H5 HA and a boost was given 4 weeks after the
priming dose. All mice remained healthy and showed no signs of
abnormal behavior after vaccination with pandemic influenza
H5N1 VLPs. The first (priming) immunization of mice with H5N1
VLPs induced low but detectable levels of antibodies as measured
by ELISA plates coated with inactivated rgDH5N1 virus antigen
(Materials and methods, Fig. 2A, 2B). The levels of virus-specific
antibodies were greatly increased two weeks after boost immuni-
zation (Fig. 2C); the 0.3 mg HA group showed significant increases
in excess of 100 fold in ELISA titers compared to those observed
after priming whereas the 0.1 mg HA group showed increases of
35 fold in antibody titers. Therefore, these results indicate that an
intranasal prime– boost immunization regimen with VLPs can
induce robust humoral antibody responses against H5N1 virus.
Dissection of the influenza-specific IgG isotypes revealed that at
28 weeks after immunization IgG2a and IgG2b are the dominant
Figure 1. Characterization of influenza H5N1 VLPs. A) A schematic diagram of wild type and mutant H5 HA. The mutant H5 HA is showing a
deletion of polybasic amino acids (RRRKK) in the cleavage region of HA (DH5 HA). B) Western blot analysis of purified H5N1 VLPs. Lane 1, Influenza
H5N1 VLPs. Lane 2, M1 VLPs lacking H5 HA. C) Cleavage of HA in VLPs. H5N1 VLPs were incubated without (2) or with (+) TPCK-treated trypsin
(2.0 mg/ml trypsin), resolved on SDS-PAGE, and probed by western blot. D) Negative stain electron microscopy of influenza H5N1 VLPs.
doi:10.1371/journal.pone.0004667.g001
Protection by H5N1 VLPs
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4667antibody components elicited by the influenza H5N1 VLPs, in
agreement with previous reports [31,33]. Interestingly, increased
IgG2a and IgG2b are responsible for the enhanced antibody levels
in the 0.3 mg HA group as compared to those in the 0.1 mgH A
group (Fig. 3A).
The functional significance of the antibody responses induced
by intranasal immunization with VLPs was evaluated by
hemagglutination inhibition (HAI) and neutralization assays.
Moderate HAI titers with a mean of 56 and standard error of
21 were elicited at 2 weeks after boost in the 0.3 mg group. Lower
HAI titers (35+/210) were detected in the 0.1 mg group, although
statistically not significant compared to those in naı ¨ve control
(Fig. 3B). In the microneutralization assay, a low titer of 40 against
the homologous VN/04 virus was elicited by the 0.3 mg dose
vaccination. These results demonstrated that H5N1 VLPs were
immunogenic when given intranasally to mice without adjuvant
and could induce moderate to low levels of HAI titers which might
have a correlation with host protection.
Long-lived protective immunity induced by influenza
H5N1 VLPs
A goal for vaccination is to induce long-lived protective
immunity. To evaluate the longevity of the response to intranasal
VLP vaccine, prime-boost immunized mice kept in isolation were
bled after 7 months to determine the duration of H5N1 virus
specific antibody levels and to compare with titers at 2 weeks after
boosting. The levels of influenza virus-specific antibodies remained
virtually unchanged at 28 weeks after immunization (Fig. 4).
To determine whether intranasal H5N1 VLP vaccination could
elicit protection against lethal infection, immunized mice were
challenged with a highly lethal dose (100 50% mouse lethal doses
[MLD50]) of the wild type VN/04 virus at 30 weeks after the boost
immunization (Fig. 5). The control animals that received PBS or
inactivated PR8/34 H1N1 virus showed clinical signs of severe
disease and significant body weight loss starting on day 3 after
virus inoculation, and died or reached the humane euthanasia
endpoint 7–9 days after challenge. In contrast, all mice immu-
nized with the low dose of H5N1 VLPs (0.1 mg HA) remained
alive by 14 days after challenge; only a transient body weight loss
was noted at day 7 but the animals recovered completely during
the following week. Mice vaccinated with the 0.3 mg dose of H5N1
VLPs were completely protected; no weight loss or apparent illness
symptoms were noted. Taken together, these results provide
evidence that H5N1 VLPs are an effective immunogen to induce
long-term protective immunity against a highly pathogenic H5N1
avian influenza virus in mice.
Replication of VN/04 virus in the lungs and systemic sites
of immunized mice
Previous studies demonstrate that VN/04 H5N1 virus is highly
pathogenic for mice as a result of its rapid systemic spread [34,35].
We investigated whether intranasal immunization with H5N1
VLPs could prevent local replication of VN/04 virus in the
respiratory tract and its systemic spread to internal organs and
brain tissue. Mice vaccinated twice with 0.3 mg H5N1 VLPs were
challenged with 10
3 pfu (100 MLD50) VN/04 virus and the
Figure 2. H5N1 Influenza virus specific total serum IgG antibody responses. A) Timeline for immunization and challenge. B) Influenza H5N1
virus specific serum IgG antibody titers at two weeks after priming by ELISA. Groups of mice (n=6) were intranasally immunized with H5N1 VLPs
(0.1 mg and 0.3 mg of HA as indicated). PBS is a mock control group of mice mock-immunized with buffer only. C) Serum IgG antibody titers to
inactivated rgDH5N1 influenza virus by ELISA at 2 weeks after boost immunization. Error bars indicate standard deviation. 0.1 mg HA and 0.3 mgH A
indicate groups of mice immunized with H5N1 VLPs containing 0.1 mg and 0.3 mg of H5 HA respectively. * Fold increases in virus-specific antibody
titers as compared to levels after priming.
doi:10.1371/journal.pone.0004667.g002
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brain and spleen to quantify the presence of wild type VN/04
virus. Viral titers in lungs were reduced by approximately 1000
fold in the H5N1 VLP immunized group compared to those in
naı ¨ve mice (Fig. 6). Viral titers in brain and spleen of VLP-
immunized mice were below the detection limit whereas
significant viral titers were in spleens of control (PBS-inoculated)
animals. Thus, our results show that immunization with H5N1
VLPs decreased viral titers in the lungs and prevented systemic
spread of VN/04 H5N1 virus in mice.
Induction of plasma and memory B cells
Differentiation and expansion of B cells as a consequence of
antigen exposure culminates with a fraction of the germinal center
B cells trafficking to the bone marrow where antigen-specific
antibody secreting plasma cells reside [36–38]. Maintenance of
virus-specific antibodies and protective immunity for over
7 months prompted us to quantify antibody secreting plasma cells
and memory B cells that might have been generated in mice
immunized with influenza H5N1 VLPs. Bone marrow and spleen
from mice immunized with H5N1 VLPs containing 0.3 mgH A
were collected at 4 weeks post prime-boost immunization.
Significant numbers of virus-specific antibody secreting bone
marrow cells were noted from H5N1 VLP-immunized mice but
not from PBS control mice within 18 hr in culture, suggesting that
pre-existing plasma cells induced by VLP vaccination were
actively secreting antibodies to H5N1 virus antigen (Fig. 7A).
After 3 days of culture, virus-specific antibody secreting cells in
splenocyte cultures surpassed those in bone marrow (Fig. 7B),
which may represent rapidly differentiated virus-specific memory
B cells. To determine the recall proliferative responses of memory
B cells in vivo, mice were either primed only or prime-boosted with
H5N1 VLPs intranasally and then 4 weeks later stimulated by
intranasal delivery of 5 mg of inactivated rgDH5N1 virus. Bone
marrow and spleen cells were collected 6 days after antigenic
stimulation with inactivated rgDH5N1 virus and analyzed for virus
specific antibody secreting cells. Significant numbers of antibody
secreting cells from both bone marrow and spleens were detected
in 18-hr cultures (Fig. 7C). Detection of virus-specific antibody
secreting cells in spleens of mice that received a single dose (H5
VLP.1) suggests the induction of memory B cells after priming.
Prime-and-boost immunized mice (H5 VLP.2) showed higher
numbers of virus-specific antibody secreting recalled B cells as
compared to mice that were primed only. Overall, these results
indicate that H5N1 VLPs can induce H5 virus specific plasma cells
as well as memory B cells.
Anamnestic mucosal immune responses
Mucosal immune responses are important for host protection
from infection by blocking initial multiplication of the pathogen at
the portal of entry. We analyzed mucosal respiratory secretions
from a group of mice that was intranasally immunized with H5N1
VLPs containing 0.3 mg HA. Significant levels of H5 virus specific
IgG antibodies were induced in nasal and tracheal washes as well
as in lung extracts of mice after prime-boost immunization with
H5N1 VLPs (H5VLP group in Fig. 8A). H5 virus-specific IgA
antibodies were also induced in lung extracts (Fig. 8B). To
determine the anamnestic virus-specific mucosal antibody re-
sponses, VLP-immunized and PBS control mice were re-
stimulated with inactivated rgDH5N1 virus (5 mg) in vivo via an
intranasal route. Respiratory secretions were collected 6 days later
and analyzed to determine the concentration of mucosal
antibodies to H5N1 by ELISA. H5 virus-specific IgG and IgA
antibodies were induced faster and accumulated to higher levels at
Figure 3. Isotypes of antibody responses induced by H5N1 VLP
immunization. Serum samples collected at week 28 post immuniza-
tion were used to determine levels of isotype antibodies specific to
influenza H5N1 virus (A, n=6) and hemagglutination inhibition titers (B,
n=5). Error bars are shown to indicate standard deviation. * (A)
Indicates statistically significant differences between 0.1 mg HA and
0.3 mg HA groups (p,0.02). ** (B) statistical significance between 0.3 mg
HA and PBS mock groups (p,0.02).
doi:10.1371/journal.pone.0004667.g003
Figure 4. Long-term maintenance of IgG antibodies specific to
influenza H5N1 virus. Serum samples collected at week 2 post
priming (week 2), at week 2 post boosting (week 6), and at week 28
before challenge infection were used to determine antibody levels
specific to H5N1 virus by ELISA with whole H5N1 inactivated virus
antigen. Antibody titers are shown as described in Materials and
methods, and error bars indicate standard deviation (n=6).
doi:10.1371/journal.pone.0004667.g004
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compared to the PBS control mice (PBS+H5i). These results
suggest that intranasal immunization with H5N1 VLPs can induce
a memory response that mediates rapid virus-specific mucosal IgG
and IgA responses upon subsequent virus antigen exposure.
Anamnestic responses of cytokine producing cells
To examine specific T cell memory induced by H5N1 VLPs,
spleen cells were harvested at 4 weeks post prime-boost immuni-
zation and analyzed for their IFN-c secreting splenocytes upon the
stimulation with an H5 HA specific peptide pool derived from A/
Thailand/16/04 (accession number APB51982, H5N1) which has
over 99% homology to VN/04 HA (Fig. 9). Higher numbers of
IFN-c secreting splenocytes specific to the HA peptide pool were
observed in the immunized animals as compared to control mice.
To determine the recall responses of memory T cells in vivo,
splenocytes were analyzed for IFN-c producing cells at day 6 after
intranasal stimulation with inactivated rgDH5N1 virus. H5N1
VLP-immunized mice showed significantly higher numbers of
IFN-c secreting cells upon stimulation with H5 HA peptide pools
corresponding to both HA1 and HA2 subunits of H5 HA as
compared to those of H5-naive mice at the time of viral antigen
challenge with inactivated rgDH5N1 virus. Therefore, H5N1 VLP
immunization of mice elicits IFN-c cytokine secreting T cells
specific to both HA1 and HA2 peptides, which can be recalled to
respond to virus exposure with fast kinetics.
Discussion
Our results demonstrate that intranasal immunization of mice
with H5N1 VLPs in the absence of adjuvant induced long-lasting
protective immunity, providing effective protection from disease
and death following a high dose lethal challenge with human
isolate of highly pathogenic avian influenza virus (H5N1). Also,
mice immunized with H5N1 VLPs elicited virus specific plasma
and memory B cells as well as mucosal antibodies and IFN-c
secreting cells, which undergo rapid in vivo expansion upon re-
encounter with viral antigen. These results highlight the potential
of non-replicating particulate VLPs as a promising subunit vaccine
whose manufacture does not require fertile eggs.
Inactivated detergent split or subunit H5N1 vaccine produced
in eggs given without adjuvants have revealed poor immunoge-
nicity in preclinical and clinical studies, requiring a high dose or
two dose immunization protocol. In humans, high doses of
baculovirus-expressed H5 HA or inactivated subunit vaccines
produced in eggs (two 90 mg HA doses) were needed to induce
antibody responses that were expected to be protective in 54 to
58% of individuals vaccinated [23,39]. Two doses of adjuvanted
inactivated H5N1 whole virus or split vaccine containing 3 mgH A
were used to induce protective immunity or to improve protection
efficacy in mice [26,40,41]. A single dose of 10
6 pfu of live
attenuated vaccine virus was weakly immunogenic and could
protect mice from lethality despite high challenge virus replication
in the respiratory tract, whereas two doses of live vaccine were
Figure 5. Protection of immunized mice from lethal infection with VN/04 influenza virus. At week 30 post immunization, H5N1 VLP
immunized and control (PBS or 5 mg inactivated PR/8/34 H1N1 virus) groups of mice were intranasally infected with 100 MLD50 of wild type H5N1
influenza virus. Mice were monitored daily for 14 days to determine the survival rate (A) and body weight changes (B). The percent of body weight
loss calculated from the initial body weight taken at day 0. Data are the average from 6 individual mice. 0.1 mg HA and 0.3 mg HA indicate the groups
of mice immunized with H5N1 VLPs containing 0.1 mg and 0.3 mg of H5 HA respectively.
doi:10.1371/journal.pone.0004667.g005
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challenge H5N1 viruses [17]. A recent study demonstrated that a
single dose of H5N1 (A/Indonesia/05/05) VLPs containing 3 mg
HA delivered via intramuscular immunization provided protection
against challenge with homologous reassortant H5N1 virus (10
LD50) in mice [31]. Our study showed that two doses of H5N1
VLPs (VN/04) containing 0.3 mg HA delivered intranasally
provided complete protection from lethal challenge with wild-
type VN/04 virus in mice without loss in body weight. Protection
from lethal challenge with VN/04 virus was also observed with
doses containing as low as 0.1 mg H5 HA in VLPs despite a
transient body weight loss. Taken together, these results indicate
that influenza H5N1 VLPs are highly immunogenic in the
preclinical mouse model. These studies point towards the need to
evaluate intranasal VLP H5N1 vaccine in humans to determine its
ability to induce protective immune responses comparable to those
of the conventional egg-grown influenza subunit vaccines with
adjuvant.
Immune correlates of protection against H5N1 viruses have not
been well defined either in animals or in humans. Hemaggluti-
nation inhibition (HAI) is a widely used serological assay for
measuring functional influenza-specific serum antibodies to HA
following immunization with inactivated vaccines. However, this
assay may be less predictive for avian H5N1 viruses whose
pathogenesis differs from that of seasonal influenza viruses.
Indeed, previous studies found less correlation between HAI titer
and protection against H5N1 virus infection [17,31]. Mice
immunized with a single intramuscular dose of H5N1 VLPs, or
recombinant subunit H5 HA (A/Indonesia/05/05) or intranasal
live attenuated reassortant virus responded with low or no
detectable HAI titers, but survived a lethal challenge [17,31].
Similarly, in this study, low or negligible HAI titers and
neutralizing activities were detected in the sera of mice that were
100% protected from lethal challenge infections (100 MLD50)b y
wild type VN/04 H5N1 virus. Our study and a previous report
[31] indicate that induction of IFN-c secreting T cell responses
may correlate with reduced viral replication in lungs and host
protective immunity. In a comparative study, H5N1 (A/
Indonesia/05/05) VLP vaccine was over 100-fold more effective
in lowering lung viral titers and morbidity than vaccination with
the equivalent amount of subunit H5 HA immunogen similar to
the egg-derived split vaccine [31]. The IgG2a isotype predomi-
nance in the H5-specific humoral antibody response indicates that
intranasal immunization with H5N1 VLPs induced Th1 biased
immune responses. In support of the postulated Th1 type
response, intranasal immunization with H5N1 VLPs induced
formation of memory T cells that could readily secrete IFN-c upon
HA peptide stimulation particularly by the HA2 region peptide.
These memory cells could be rapidly recruited to the respiratory
tract and might contribute to lowering lung viral titers. Previous
studies have shown that T cell responses may play a role in
providing protection. Intramuscular immunization with H5N1
VLPs [31] and vaccination with HA-expressing adenoviruses [24]
suggested that T cell responses to the HA2 region contributed to
protection against heterologous homotypic strains in the absence
of a strong humoral neutralizing response.
Inclusion of additional influenza proteins besides HA may
partially contribute to protection particularly when neutralizing
(and/or HAI) antibody responses are low or undetectable. The
NA component of H5N1 VLPs may contribute to protection
against morbidity and mortality in the absence of neutralizing
activities as reported previously [42–46]. Similarly, the M1
component of H5N1 VLPs elicits CD8 T cell responses that
contribute to partial protection as noted earlier [47,48]. Studies on
the possible role of these proteins in VLP-induced protective
immunity are under way.
A primary goal of vaccination is to induce memory responses
that will provide long-lived protection against severe disease by the
pathogen. However, currently available inactivated influenza
vaccines do not induce long-lasting immune responses. Antibody
levels elicited by inactivated influenza virus vaccine administered
intramuscularly have been observed to gradually decline by 75%
over an eight-month period [49]. We have shown that
intramuscular immunization of mice with influenza VLPs
containing H1 HA (PR/8/34) induced long-term protective
immunity over 14 months [30]. In this study, intranasal
immunization of mice with H5N1 VLPs induced virus specific
antibodies that lasted for the 7 month period analyzed. Further-
more, immunized mice challenged with a high dose of wild type
virus were completely protected from morbidity and mortality.
Also, virus specific antibody secreting plasma cells and memory B
cells widely regarded as long-lived were identified in bone marrow
and spleens, respectively. These results are consistent with the
postulated generation of host-protective memory immune re-
sponses by H5N1 VLP immunization.
VLPs administered intranasally to BALB/c mice are likely to be
taken up by microfold epithelial cells in the nasal compartment
and transferred to nasal associated lymphoid tissue to subsequently
traffic through peripheral lymph nodes into spleen [50], inducing
mucosal as well as systemic immune responses. The generation of
memory immune responses was further confirmed by assays using
both in vivo antigen challenge and in vitro stimulation. In addition to
long-lived plasma cells maintaining serum antibody levels,
intranasal VLP immunization induced memory B cells that
rapidly expand and differentiate into antibody secreting cells after
exposure to viral antigen. Detection of antibody secreting cells in
bone marrow suggested that a population of antibody secreting
cells derived from memory B cells may traffic to the bone marrow.
Figure 6. Replication of wild type VN/04 virus in mice
immunized with H5N1 VLPs. Mice intranasally immunized twice
with influenza H5N1 VLPs containing 0.3 mg H5 HA were infected with
100 MLD50 dose of VN/04 virus at 4 weeks after the second
immunization. At day 4 after virus inoculation, mice were euthanized
and lung, brain, and spleen were collected from individual mice. Virus
titer in the lung homogenate was determined by plaque assay on
MDCK cells. Data are the mean virus titers from 4 individual mice+/
2Standard Error of the Mean (SEM). Dashed horizontal line indicated
lower limit of detection. *, Indicated virus was isolated from one mouse.
doi:10.1371/journal.pone.0004667.g006
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with virus-specific anamnestic mucosal IgG and IgA antibody
kinetics, whereas in vitro stimulation revealed influenza-specific
IFN-c secreting splenocytes. To our knowledge, this is the first
reported evidence of induction of memory B and T cell responses
by intranasal immunization with H5N1 VLPs, and their rapid
expansion in both mucosal and systemic sites upon viral antigen
encounter.
Adult populations have a certain level of pre-existing immunity
against seasonal influenza virus, but most humans still respond to
annual vaccination. Therefore, it is likely that host immune responses
to VLP antigens would not be affected by the presence of pre-existing
immunity to influenza A. Nonetheless, it will be important to
determine the immunogenicity of pandemic H5VLPs in the presence
of immunity to seasonal influenza virus. Also, immune responses to
VLPs in aged mice will provide helpful insight into vaccinating the
elderly populations which are more susceptible to influenza infection.
An influenza vaccine providing broadly cross protective immunity is
highly desirable. Mice immunized intranasally or intramuscularly
with A/PR/8 (H1N1) VLPs were found to be protected against
heterologous challenge with A/WSN (H1N1) virus [29,30]. In
another recent study, mice vaccinated with A/Indonesia/05 VLPs
Figure 7. Generation of virus specific plasma and memory B cells in mice immunized with H5N1 VLPs. A) Generation of virus specific
antibody secreting plasma cells. Groups of mice (n=6) were intranasally immunized with influenza H5N1 VLPs (containing 0.3 mg HA) or PBS buffer at
weeks 0 and 4. At 4 weeks post immunization, bone marrow and spleen cells were prepared and in vitro cultured for 18 hrs on plates coated with
inactivated rgDH5N1 virus to detect the antibody secreting cell spots. B) Antibody secreting cells after 3-day culture stimulation. The bone marrow
and spleen cells were from the same group of mice as in A except the 3-day in vitro culture. C) Antibody secreting cells after 18 hrs culture. Groups of
mice (n=6) were intranasally immunized once (H5 VLP.1+H5i) or twice (H5 VLP.2+H5i) (weeks 0 and 4) with influenza H5N1 VLPs (containing 0.3 mg
HA) or PBS buffer (PBS+H5i) and were administered with inactivated rgDH5N1 virus (2.5 mg) 6 days earlier before euthanasia. *, ** indicate statistically
significant differences between bone marrow and spleen (p,0.05 and p,0.01 respectively) as determined by Student’s 2-tailed t-test.
doi:10.1371/journal.pone.0004667.g007
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challenge with an A/Viet Nam H5N1 reassortant virus [31]. Thus,
mice intranasally immunized with H5N1 (A/VN) VLPs would be
expected to protect against heterologous H5N1 strains such as A/
Thailand/16/04 or A/Indonesia/05/05 although the extent of cross
protection among different influenza strains remains to be deter-
mined.
In summary, unadjuvanted influenza H5N1 VLPs are immu-
nogenic in mice and were found to induce long-term protective
immunity as well as to generate immunologic memory for rapid
recall responses. Non-replicating particle-based VLP approaches
circumvent the need for handling live influenza viruses in vaccine
manufacturing. We have not observed any abnormal symptoms in
mice immunized with pandemic influenza H5N1 VLPs or seasonal
influenza VLPs. Therefore, the results of this preclinical study
indicate that influenza H5N1 (VN/04) VLPs are highly immuno-
genic and have the potential to be developed as an effective
vaccine inducing long-term protective immunity.
Materials and Methods
Virus and cells
The highly pathogenic avian influenza H5N1 virus A/Viet
Nam/1203/04 (VN/04) isolated from a fatal human infection and
the reassortant virus (rgDH5N1) produced by reverse genetic
techniques [17,26,27] were used in the study. The rgDH5N1 virus
contains HA modified at the cleavage site (Fig. 1A) and NA
derived from H5N1 virus VN/04 and internal proteins from
H1N1 virus A/Puerto Rico/8/34 (PR/8/34). A/Puerto Rico/8/
34 (H1N1) was obtained from American Type Culture Collection
(ATCC). Viruses were propagated in the allantoic cavity of 10-
days-old embryonated chicken eggs. Virus containing allantoic
fluid was harvested, aliquoted and frozen at 280uC until used in
experiments. Purified virus was prepared by equilibrium and
differential sucrose density gradient separations [51]. VN/04 virus
was used in animal challenge experiments and for the isolation of
viral RNA. All experiments with live H5N1 virus were performed
in biosafety level 3 enhanced laboratory facilities. Reassortant
virus rgDH5N1 was inactivated with formalin, concentrated and
purified by centrifugation, and used as an ELISA antigen as well as
in vivo and in vitro viral antigen stimulator. Spodoptera frugiperda
Sf9 cells were maintained in suspension in serum free SF900II
medium (GIBCO-BRL) at 27uC in spinner flasks at a speed of 70–
80 rpm. Madin-Darby canine kidney (MDCK) cells were obtained
from ATCC and were cultured in Dulbecco’s Modified Eagle’s
Medium supplemented with 10% fetal bovine serum.
DNA constructs, recombinant baculoviruses, and
production of VLPs
The cDNA fragments encoding HA, NA, or M1 proteins
derived from influenza H5N1 virus (VN/04) were generated using
RT-PCR and cloned into the pCI plasmid vector (Promega). The
H5 HA cDNA was mutated to delete the polybasic amino acids in
the HA1/HA2 cleavage region as shown in the Fig. 1A. The HA
encoding gene in the pCI vector was treated with Xho I, Klenow
polymerase fragment, then subsequently digested with Sal I, and
cloned into the pFastBac plasmid, a baculovirus (BV) transfer
vector (Invitrogen). The NA cDNA in pCI was PCR-amplified
using the following primers: F-NA-EcoRI, 59 AAGAATTC
CCACCATG AAT CCA AAT CAG AAG ATA ATA 39 and
R-NA-XbaI, 59 AG TCTAGA CTA CTT GTC AAT GGT GAA
TGG 39. The M1 cDNA was PCR-amplified using the primers: F-
M1-Sma I, 59 TCC CCCGGG CCACCATGAGCCTT CTG
ACC GAG GTC 39 and R-M1-Xba I, 59-TTACT TCTAGA
TTACTTGAATCG CTG CAT CTG 39 (underline denotes
restriction enzyme recognition sites). The PCR-amplified NA and
M1 encoding DNA fragments were digested with corresponding
restriction enzymes and cloned into the pFastBac plasmid under
the polyhedron promoter, and confirmed by DNA sequencing.
Figure 8. Mucosal antibody responses. A) Virus specific mucosal
IgG. B) Virus specific mucosal IgA. H5VLP indicate a groups of mice
(n=6 for each group) that was intranasally immunized with H5N1 VLPs
containing 0.3 mg H5 HA at weeks 0 and 4. PBS is a mock control.
H5VLP+H5i and PBS+H5i indicate additional groups of mice that were
intranasally administered with inactivated rgDH5N1 virus (2.5 mg)
6 days earlier before euthanasia (in vivo viral antigen exposure). Nose,
trachea, and lung samples from individual mouse were prepared in
200 ml, 200 ml, and 1000 ml PBS buffer respectively. Diluted samples
(106) were used to determine antibody responses on ELISA plates
coated with inactivated rgDH5N1 virus and optical densities were read
at 450 nm. * p,0.05 compared to the PBS control. ** p,0.05 compared
to H5VLP.
doi:10.1371/journal.pone.0004667.g008
Figure 9. IFN-c ELISPOT. Naı ¨ve, unimmunized mouse control, H5VLP,
H5VLP+H5i and N (naı ¨ve)+H5i, groups of mice (n=6 for each group)
intranasally immunized as described in the legend of Fig. 8. Spleen cells
were collected from individual mouse and stimulated with H5 HA1 or
H5 HA2 peptide pool derived from A/Thailand/16/04 (H5N1). * and **
indicate significant differences between H5VLP+H5i and H5VLP or
PBS+H5i group (p,0.05 and p,0.005, respectively) as determined by
Student’s 2-tailed t-test.
doi:10.1371/journal.pone.0004667.g009
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NA, M1 respectively, recombinant Bacmid baculovirus DNAs
(rAcNPV) were isolated from transformed DH10Bac cells with
pFastBac plasmid constructs and used to transfect Spodoptera
frugiperda Sf9 insect cells following the manufacturer’s instruc-
tions (Invitrogen). The virus titer was determined with a Fast Plax
titration kit according to the manufacturer’s instructions (Novagen,
Madison, WI). The expression of H5N1 structural proteins in
infected insect cells was confirmed by western blot using rabbit
anti-HA or NA polyclonal antibodies (ProSci Inc.,) or mouse anti-
M1 antibody (Serotec).
To produce influenza H5N1 VLPs, Sf9 insect cells were co-
infected with rBVs expressing HA, NA, and M1, and VLPs were
harvested from the culture supernatants by centrifugation and
purified using sucrose gradient ultracentrifugation as described
[29,30]. HA contents in VLPs were determined by western blot in
comparison with the purified H5 HA protein (Biodefense and
Emerging Infections Research Resources Repository) derived from
the influenza virus VN/04 as a standard. The electron
microscopic examination of purified H5N1 VLPs was carried
out as described previously [29]. The functional characterization
of HA on VLPs was performed by analyzing hemagglutination
activity and trypsin cleavability assays as described [29,30].
Influenza H5N1 VLPs used in this study contained approximately
10% H5 HA relative to total protein of VLPs, similar to previously
reported values for H1N1 VLPs [30].
Immunization and challenge
Female inbred BALB/c mice (Charles River) aged 6 to 8 weeks
were housed in the facility of Emory University following the
approved IACUC protocol. Groups of mice (6 mice per group)
were intranasally immunized with 50 ml of influenza H5N1 VLPs
containing 0.1 mg or 0.3 mg of H5 HA at weeks 0 and 4 under a
slight anesthesia condition with isofluorane. Two groups of 6 mice
each were mock-immunized with PBS or immunized with 3 ug of
inactivated A/PR/8/34 purified following the same schedule as
for VLP groups. H5N1 VLP-immunized and control mice were
transferred to the enhanced animal biosafety level 3 facilities in the
Centers for Disease Control and Prevention (Atlanta, GA, USA)
for virus challenge studies. Animals were anesthetized by
isoflurane (Butler Animal Health Supply) inhalation and inoculat-
ed intranasally with 50 ml of sterile PBS containing 10
3 plaque
forming units (pfu), approximately 100 of 50% mouse lethal doses
(MLD50) of VN/04 virus. Mice were observed and weighed daily
starting immediately before challenge, to monitor health status.
The humane endpoint of the challenge studies was body weight
loss of $20% relative to the weight at the time of challenge
inoculation. Animal study protocols were performed in compli-
ance with institutional and federal guidelines. For determination of
lung viral titers, mucosal immune responses, and cytokine
ELISPOT and memory B cell assays, additional sets of mice were
intranasally immunized with H5N1 VLPs containing 0.3 mgH 5
HA, and some groups of these mouse groups were intranasally
administered with 5 mg of inactivated reassortant rgDH5N1 virus
6 days earlier prior to euthanasia and organ sample collection.
Antibody responses, isotypes, and hemagglutination
inhibition titer (HAI)
Blood samples were collected by retro-orbital plexus puncture
before immunization and at various time points post-immuniza-
tion (at week 2 after priming and at week 6 and 28 after boosting).
Influenza virus specific antibodies IgG, isotypes IgG1, IgG2a,
IgG2b, and IgA were determined in sera by enzyme-linked
immunosorbent assay (ELISA) as described previously [29]. 96-
well microtiter plates (Nunc Life Technologies, Rochester, NY.)
were coated with 0.4 mg of sucrose gradient purified egg-grown
inactivated rgDH5N1 virus in 100 ml of coating buffer (0.1 M
sodium carbonate, pH 9.5, 4 mg inactivated rgDH5N1 virus per
ml) at 4uC overnight. For antibody titers, dilutions giving 2-fold
higher OD450 values than the standard deviation compared to the
those of naı ¨ve control samples were considered as positive.
Hemagglutination-inhibition (HAI) titers were determined by
standard methods using 4 HA units of inactivated rgDH5N1 and
1-% horse erythrocyte suspension [52]. Microneutralization assays
were performed as described previously [53,54].
Plasma cells and memory responses
A group of mice (n=6) was intranasally immunized with
influenza H5N1 VLPs containing 0.3 mg HA at weeks 0 and 4.
Cells from bone marrow and spleens of mice at week 4 post
immunization or control mice (PBS) were prepared as described
[55]. Freshly isolated bone marrow and spleen cells (1610
6 cells)
were added to the Multiscreen 96-well filtration plates (Millipore)
coated with inactivated rgDH5N1 virus antigen. After incubation
for 18 or 72 hrs at 37uC with 5% CO2, bound antibody was
detected using an ELISPOT kit with HRP-conjugated anti-mouse
Ig and diaminobenzidine for color development following the
manufacturer’s instructions (Research Genetics). The antibody-
secreting cell spots were recorded per 10
6 input cell numbers. In
another set of experiments to determine anamnestic responses,
H5N1 VLP-immunized mice were administered with 5 mgo f
inactivated rgDH5N1 virus intranasally 6 days earlier, and bone
marrow and spleen cells were analyzed for cytokine production
and virus-specific antibody secreting cells.
Cytokine assays
Antibodies against mouse cytokines used in cytokine ELISPOT
assays were purchased from BD/Pharmingen (San Diego, Calif.).
Anti-mouse interferon-c (IFN-c) and IL-4 antibodies (3 mg/ml in
coating buffer) were used to coat Multiscreen 96-well filtration
plates (Millipore). Freshly isolated splenocytes (1.5610
6 cells) were
added to each well and stimulated with an HA1 or HA2 subunit
peptide pool at a concentration of 10 mg/ml. Peptide pools are 15-
mer peptides with 11 amino acid overlap derived from A/
Thailand/16/04 (H5N1) which has over 99% homology to VN04
HA. The plates were incubated for 36 hrs at 37uC with 5% CO2.
Development and counting of cytokine ELISPOTs were per-
formed as described [29].
Viral titers
Mice in groups of 4 received intranasally as described above two
doses of 0.3 mg HA each of H5N1 VLPs. Control group of 4
animals received PBS alone. Four weeks after the second VLPs
immunization mice were inoculated with 10
3 pfu (100 MLD50)o f
VN/04 virus as described above. Mice were euthanized on day 4
after virus inoculation, and lungs, brain, and spleen were
harvested. Organs were homogenized in 1 ml of sterile PBS with
antibiotics; homogenates were clarified by centrifugation. Virus
titers were determined by plaque assay in MDCK cells and
expressed as log10 of pfu in 1 ml of organ homogenate. The limit
of virus detection was 50 pfu (1.69 log10) per 1 ml.
Statistical analysis
All immunological parameters were recorded for individuals
within groups. Statistical comparisons of data between groups
were calculated by Student’s 2-tailed t-test. A value of P,0.05 was
considered significant
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